Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Adults aged 18 years or older, regardless of the gender;
2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease);
3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available;
4. Availability of the baseline and follow-up annotations.
Exclusion Criteria:
* None
Primary outcome measure(s)
Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT — 30 months: from the end of samples collection to the end of study analysis
Quantification and qualification of lesions acquired at the time of HT. — 30 months: from the end of samples collection to the end of study analysis
Prevalence of clonal relationship between SMZL and HT — 30 months: from the end of samples collection to the end of study analysis
Trial sites (7)
Facility
City
Region
Status
Columbia University
New York
New York
Not Yet Recruiting
Universitz Hospitals Leuven
Leuven
Belgium
Not Yet Recruiting
Hôpital Saint Louis
Paris
France
Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia
Italy
Recruiting
Hospital Clínic de Barcelona
Barcelona
Spain
Recruiting
Oncology Institute of Southern Switzerland
Bellinzona
Switzerland
Not Yet Recruiting
University Hospitals Dorset
Bournemouth
United Kingdom
Not Yet Recruiting
More International Extranodal Lymphoma Study Group (IELSG) trials in Switzerland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
